Innoviva Specialty Therapeutics Antimicrobial Therapies, XACDURO, ZEVTERA and NUZOLVENCE Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the companys infectious disease therapies, XACDURO (sulbactam/durlobactam for injection), ZEVTERA (ceftobiprole medocaril sodium for injection), and NUZOLVENCE (zoliflodacin) are...